

PRESS RELEASE

CardioSecur receives TGA clearance and is now available in Australia

Clinical-grade app-based mobile 22-lead ECG technology with only 4 electrodes for medical professionals, industry partners and patients is now available in Australia

Melbourne, 15. April 2021. The Frankfurt-based MedTech company has announced today that the Australian Therapeutic Goods Administration (TGA) has granted the company clearing for its cutting-edge app-based mobile ECG devices. With up to 22-leads and only 4 electrodes, CardioSecur even outshines the so-called "*Gold Standard*" and allows a synchronous 360° diagnostic view of the heart without compromising ease of use. CardioSecur is remarkably intuitive. Not only medical professionals but also non-medical staff as well as patients themselves may easily take a profound ECG in just 30 seconds. CardioSecur maximizes a doctor's diagnostic power to reveal any type of arrhythmia including atrial fibrillation and life-threatening ischemia on any side of the heart.

The successful TGA certification process is the result of over a year of in-depth audit and assessment of the quality and safety of the CardioSecur product portfolio. *"CardioSecur has a long track record when it comes to quality and safety of its medical devices. Therefore, we are especially proud to bring our mobile app-based ECG devices and platform services to the Australian market,"* says Prof. Dr. Markus Riemenschneider, founder and Managing Director of CardioSecur.

CardioSecur Pro is the ECG solution for medical professionals, nurses and industry sectors challenged by mobility and communication like the aviation sector. CardioSecur Pro is worldwide the first clinical ECG system fully meeting the guidelines of the European Society of Cardiology (ESC) by providing a 22 lead ECG with only 4 electrodes that operates a 360° evaluation of the heart in one synchronous reading. It is the only system that thereby identifies ischemia on any wall of the

heart and is capable of capturing and localizing even the most complex arrhythmias. CardioSecur's ECG capabilities are process focussed. The technology is augmented by platform services connecting and integrating the relevant stakeholders within a medical information network. Such networks experience higher process efficacy and secure data availability. ECG technology has never been more sophisticated.

Personal MedSystems GmbH develops and sells fully approved class IIa medical ECG systems Made in Germany, GDPR and ISO 27001 compliant information services for healthcare professionals, nurses, industry partners and patients under the name CardioSecur.

Additional information at www.cardiosecur.com

Press contact:

Personal MedSystems GmbH

Eduard Lerperger

Phone +49 (0) 151-19120692

press@cardiosecur.com



CardioSecur used by medical professionals ©CardioSecur